The most widely used cholesterol medications fall into five categories, each working differently to lower LDL (“bad”) cholesterol. Statins remain the first-line treatment for the vast majority of people, but several powerful alternatives now exist for those who need additional lowering or can’t tolerate statins. Here are the five most clinically significant types of cholesterol medication, what they do, and what to expect from each.
1. Statins
Statins are the most commonly prescribed cholesterol drugs in the world, and for good reason. They block an enzyme your liver needs to produce cholesterol, which forces your body to pull LDL out of the bloodstream instead. High-intensity statins like atorvastatin (Lipitor) and rosuvastatin (Crestor) can reduce LDL cholesterol by 50% or more. Moderate-intensity options, including pravastatin and simvastatin, typically lower LDL by 30% to 49%.
Statins also have benefits beyond cholesterol numbers. They stabilize plaques already lining your arteries, making them less likely to rupture and cause a heart attack. This is why current guidelines recommend them not just for high cholesterol but for anyone with established cardiovascular disease or a high 10-year risk of developing it.
The most talked-about side effect is muscle pain. Somewhere between 10% and 25% of patients on statins report muscle symptoms like aching, cramping, or soreness. However, when researchers compared statins to placebo pills in blinded trials, muscle complaints occurred at nearly identical rates in both groups (about 12.5%), suggesting that many cases may be driven by expectation rather than the drug itself. That said, some people do experience genuine muscle problems, and switching to a different statin or lowering the dose often resolves them. Statins are also linked to a modest increase in the risk of developing type 2 diabetes, though for most people the cardiovascular benefit far outweighs this risk.
2. Ezetimibe (Zetia)
Ezetimibe works in a completely different way from statins. Instead of blocking cholesterol production, it sits in your small intestine and prevents cholesterol from being absorbed into your bloodstream. On its own, it lowers LDL by about 18%. That’s modest compared to a statin, but ezetimibe’s real value is as a partner drug. When added on top of a statin, it can push LDL down an additional 21% to 30%.
This combination matters because current guidelines set aggressive targets for people with heart disease. If you’ve had a heart attack or stroke, the goal is typically an LDL below 70 mg/dL, and for very high-risk patients, below 55 mg/dL. Many people can’t reach those numbers with a statin alone, and ezetimibe is often the first add-on drug recommended. It’s a daily pill with very few side effects, which makes it a practical next step before moving to injectable medications.
3. PCSK9 Inhibitors (Repatha and Praluent)
PCSK9 inhibitors are injectable medications that represent a major leap in cholesterol-lowering power. Your liver has receptors that grab LDL particles out of the blood, and a protein called PCSK9 breaks down those receptors. By blocking PCSK9, drugs like evolocumab (Repatha) and alirocumab (Praluent) allow your liver to clear far more LDL from your bloodstream.
The results are dramatic. These drugs reduce the risk of major cardiovascular events (heart attacks, strokes, and related emergencies) by roughly 15% to 20% compared to placebo. Evolocumab specifically reduces heart attack risk by 27%. Both medications are self-injected at home, typically every two weeks or once a month depending on the formulation.
The main barriers are cost and convenience. PCSK9 inhibitors are significantly more expensive than statins or ezetimibe, and insurance coverage can require prior authorization. They’re generally reserved for people with established cardiovascular disease who haven’t reached their LDL goal on other medications, or for people with familial hypercholesterolemia, a genetic condition that causes extremely high cholesterol from birth.
4. Inclisiran (Leqvio)
Inclisiran is the newest approach to cholesterol management. It uses a technology called small interfering RNA to silence the gene that tells your liver to make PCSK9. The practical result is similar to PCSK9 inhibitors, but the dosing schedule is radically different: one injection at the start, another at three months, and then just one injection every six months.
In clinical trials, inclisiran lowered LDL by 48% to 52% compared to placebo, sustained over time. For people who struggle with daily pills or frequent injections, getting treated twice a year at a doctor’s office is a significant advantage. Unlike Repatha and Praluent, which you inject yourself at home, inclisiran is administered by a healthcare provider. It’s used alongside a statin, not as a replacement, and is approved for people with cardiovascular disease or familial hypercholesterolemia who need additional LDL lowering.
5. Bempedoic Acid (Nexletol)
Bempedoic acid was developed specifically for people who can’t tolerate statins. It blocks an enzyme involved in cholesterol production, similar to statins, but it works a step earlier in the process and is only active in the liver. Because it doesn’t affect muscle tissue the way statins can, it avoids the muscle pain that drives many people to stop statin therapy.
On its own, bempedoic acid provides a moderate LDL reduction. But in its combination formulation with ezetimibe (sold as Nexlizet), it can lower LDL by 35% to 40%. The CLEAR Outcomes trial confirmed that bempedoic acid also reduces the risk of cardiovascular events in statin-intolerant patients, making it the first non-statin pill proven to do so. It’s a daily oral medication, which many people prefer over injections.
How These Medications Work Together
Cholesterol treatment is rarely a single-drug approach anymore, especially for higher-risk patients. The 2026 ACC/AHA guidelines lay out a clear ladder. For people at intermediate cardiovascular risk, the LDL target is below 100 mg/dL. For those at high risk or with existing heart disease, the target drops to below 70 mg/dL. And for very high-risk patients, the goal is below 55 mg/dL.
Most people start with a statin. If that doesn’t get LDL low enough, ezetimibe is typically added next. If the combination still falls short, a PCSK9 inhibitor, inclisiran, or bempedoic acid enters the picture, chosen based on how much additional lowering is needed and whether you prefer pills or injections. This stepwise approach means your treatment may evolve over time as your doctor checks your numbers and adjusts accordingly.
Choosing the Right Medication
The best cholesterol medication for you depends on several factors: how high your LDL is, whether you have existing heart disease, how you respond to statins, and your personal preferences around pills versus injections. Statins remain the starting point for most people because they’re effective, inexpensive, and backed by decades of evidence showing they prevent heart attacks and strokes. The newer options fill important gaps for people who need more aggressive treatment or who experience side effects that make statins impractical.
Cost varies enormously across these five categories. Generic statins and ezetimibe cost a few dollars per month. Bempedoic acid runs significantly higher. PCSK9 inhibitors and inclisiran carry the highest price tags, though manufacturer programs and insurance negotiations have brought costs down considerably from their original levels. Your insurance formulary will often play a major role in determining which medications are accessible to you.